JPMorgan’s top stock ideas for 2026
Alphabet and Allstate are among the JPMorgan’s top ideas for a year in which AI will continue to drive the market.
Uncategorized
Here are the biggest IPOs of 2025 and how they performed
This week, Medline launched the biggest IPO of 2025. But, it wasn’t the only large public listing this year, according to a CNBC Pro data analysis.
Stocks To Buy: Aditya Birla Group stock can rise up to 60%, projects Motilal Oswal’s bull case
Aditya Birla Real Estate has a pipeline totaling nearly ₹70,000 crore in Gross Development Value (GDV) over the next two to four years. This includes ₹5,100 crore in unsold inventory from ongoing projects, ₹46,200 crore from upcoming launches and ₹18,600…
Aarti Industries secures long-term methanol, toluene supply contracts
Aarti Industries Ltd signed long-term methanol and toluene supply deals with GCC and South-East Asia firms, boosting feedstock security and reporting strong Q2 FY26 financial growth.
Three defence stocks that can fetch up to 44% returns on ‘multi-decade transformation’: Phillip Capital
Shares of Mazagon Dock are down 37% from their record high levels of ₹3,775, while those of Cochin Shipyard and Garden Reach are down 40% and 37% respectively from their record high levels that they had surged to earlier this…
Shree Cement shares fall after Chhattisgarh plant lockout to result in production shortage
Based on current operations, Shree Cement estimates a loss of cement production of around 10,000 tonnes per day, as per its exchange filing.
SEBI’s expense ratio tweak to have limited impact on mutual fund profits: SBI MF’s DP Singh
SEBI’s expense ratio changes are less damaging than feared, say Amisha Vora of PL Capital and DP Singh of SBI Mutual Fund, though brokers face near-term pressure.
Indus Towers shares do not have a favourable risk-reward, Motilal Oswal says despite likely VIL relief
While any potential relief for Vodafone Idea is sentimentally positive for Indus Towers, Motilal Oswal is of the view that the risk reward is uncompelling at the current market price.
This is the biggest trigger behind the surge in Indian Pharma stocks on Friday
Brokerage firm Macquarie is of the view that incremental projects, resulting from the US Biosecure Act, are expected to contribute to revenue and earnings only after a lag that will last between 12 months to 24 months.
‘Buy Lenskart’ is Macquarie’s advice as it sees 29% upside
The brokerage described Lenskart as India’s leading eyewear retailer with a fully integrated supply chain, which provides a competitive edge in costs, design and operating efficiency compared with peers.